½ÃÇè°ú¸ñº° °øÁö»çÇ×

  • ½ÃÇè¾È³»
  • ½ÃÇè°ú¸ñº° °øÁö»çÇ×

2025³âµµ Á¦3ȸ Àü¹®¾à»ç ÀڰݽÃÇè °øÁö»çÇ×

- Á¾¾ç -

1½ÃÇè³»¿ë ±¸¼º ¹× ½ÃÇè½Ã°£ (Àü °ú¸ñ °øÅë»çÇ×)

1)½ÃÇè³»¿ëÀº °øÅ뿵¿ª°ú Àü¹®¿µ¿ªÀ¸·Î ±¸¼ºµÊ.

  • °øÅ뿵¿ª : ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò
  • Àü¹®¿µ¿ª : Á¾¾ç

2)½ÃÇè½Ã°£

  • ÃÑ ½ÃÇè½Ã°£ : ½ÃÇèÁغñ ¹× ¾È³», °øÁö½Ã°£ µîÀ» Æ÷ÇÔÇÏ¿© 180ºÐ(3½Ã°£).

2ÃâÁ¦À¯Çü ¹× ¹èÁ¡

1)°øÅ뿵¿ª(ÃÑ20Á¡) : °´°ü½Ä 20¹®Ç× (°¢ 1Á¡)

2)Àü¹®¿µ¿ª(ÃÑ80Á¡) : °´°ü½Ä 80¹®Ç× (°¢ 1Á¡)

  • ¾à¹°¿ä¹ýÀÇ ÀûÀý¼º °ËÅä
  • ¾à¹°¿ä¹ý °ü·Ã ¹®Á¦(drug-related problems) ÆÄ¾Ç ¹× ÇØ°á¹æ¾È Á¦½Ã
  • ȯÀÚ ¸ÂÃãÇü ¾à¹° ¼±Åà ¹× ¾à¹°¿ä¹ý °èȹ ¼ö¸³
  • ¾à¹°¿ä¹ýÀÇ Ä¡·áÈ¿°ú ¹× ¾à¹° ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ
  • ȯÀÚ º¹¾à»ó´ã ¹× ±³À°

3ÃâÁ¦¹üÀ§

1)°øÅ뿵¿ª ÃâÁ¦¹üÀ§ : ÀǾàÅë°èÀÇ ±âº»°³³ä ¹× À̸¦ Ȱ¿ëÇÑ ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë µî¿¡ °üÇÑ ¹®Ç×À¸·Î ÀÌ·ç¾îÁü.

  • ±Ù°Å±â¹ÝÀÇÇÐ(Evidence-Based Medicine) ¹× ±Ù°Å±â¹ÝÀÓ»ó½Ç¹«(Evidence-Based Clinical Practice, EBCP)ÀÇ ÀÌÇØ
  • ÀǾ๮ÇåÀÇ Á¾·ù ¹× Ư¡
  • ÀÓ»óÅë°èÀÇ ±âº» °³³ä
  • ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë

2)Àü¹®¿µ¿ª ÃâÁ¦¹üÀ§

  • °íÇüÁ¾¾ç: Æó¾Ï, ´ëÀå¾Ï, À¯¹æ¾Ï, À§¾Ï, ÃéÀå¾Ï, °£¾Ï, ½ÅÀå¾Ï, Àü¸³»ù¾Ï, ³­¼Ò¾Ï, ¾Ç¼º Èæ»öÁ¾
  • Ç÷¾×Á¾¾ç: ¹éÇ÷º´, ¸²ÇÁÁ¾, Á¶Ç÷¸ð¼¼Æ÷À̽Ä, ´Ù¹ß°ñ¼öÁ¾
  • ¼Ò¾ÆÁ¾¾ç (Ç÷¾×Á¾¾ç ÆÄÆ®)
  • Ç×¾ÏÄ¡·áÀÇ ¿øÄ¢ ¹× º¸Á¶Àû Ä¡·á¿Í ÁöÁö¿ä¹ý
  • ¾ÏÁ¾º° À§ÇèÀÎÀÚ, ¿¹¹æ ¹× °ËÁø (´Ü, °ËÁø ±Ç°í¾ÈÀº ¿ì¸®³ª¶ó ±âÁØÀÓ)

4Âü°í¹®Çå

1)Àü °ú¸ñ °øÅë Âü°í¹®Çå

°¡)¾à¹°Ä¡·áÇÐ °ü·Ã Âü°í¹®Çå

  • DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 12th ed., 2023.
  • Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 12th ed., 2023.
  • Zeind CS, Carvalho MG, Cheng JW, Zaiken K, LaPointe T, eds. Applied Therapeutics: The Clinical Use of Drugs. 12th ed., 2023.
  • Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver PB, Lee KC. Pharmacotherapy Principles & Practice. 6th ed., 2022.
  • Çѱ¹ÀÓ»ó¾àÇÐȸ. ¾à¹°Ä¡·áÇÐ Á¦6°³Á¤. ½ÅÀϺϽº. 2025

³ª)°øÅ뿵¿ª(ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò) °ü·Ã Âü°í¹®Çå

  • ¾à±¹½Ç¹«ºÐ°úȸ, ¾à·áÁ¤º¸ÇÐ, ½ÅÀϺϽº, 2021³â, Section III, Á¦ 9-13Àå, 16Àå
  • ¾à±¹½Ç¹«ºÐ°úȸ, ÀÓ»ó½Ç¹«¾àÇÐ, ½ÅÀϺϽº, 2024³â, 27Àå, 29Àå
  • Guyatt G, Rennie D, Meade MO & Cook DJ. Users¡¯ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed., New York, USA: McGraw Hill Education & The JAMA Network. 2015.
  • DiCenzo R, ed. Clinical Pharmacist's Guide to Biostatistics and Literature Evaluation. 2nd ed., Lenexa, KS, USA: American College of Clinical Pharmacy. 2015.
  • Browner WS, Thomas B Newman TB, Cummings SR. Designing Clinical Research. 5th ed. Wolters Kluwer. 2022.
  • Malone PM, Witt BA, Malone MJ, Peterson DM. Drug Information: A Guide for Pharmacists, 7th ed. McGraw Hill. 2022.
  • Canadian Medical Association Journal (CMAJ) evidence based medicine (EBM) series
    • Wyer PC, et al. Tips for learning and teaching evidence-based medicine: Introduction to the series. CMAJ 2004;171:347-8.
    • Barratt A, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.
    • Montoria VM, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2005;171:611-5.

2)Àü¹®¿µ¿ª °ü·Ã Âü°í¹®Çå

  • ´ëÇÑÇ÷¾×ÇÐȸ Àú. Ç÷¾×ÇÐ, 2018
  • ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ Àú. ÀÓ»óÁ¾¾çÇÐ, 2020
  • °¡À̵å¶óÀÎ ¹× ±âŸ Âü°í
    * ¼öÇè»ýÀÇ ½ÃÇè Áغñ±â°£À» °í·ÁÇÏ¿© Âü°í¹®Çå ¹ßÇ¥ÀÏÀÎ 2025.7.31. Àü±îÁö ¹ßÇ¥µÈ °¡À̵å¶óÀÎ ¹× Çã°¡ÀǾàǰÀ» ½ÃÇè¹üÀ§¿¡ Æ÷ÇÔÇÔ
    • NCCN (National Comprehensive Cancer Network) http://www.nccn.org
    • ASCO (American Society of Clinical Oncology) http://www.asco.org
    • ±¹°¡¾ÏÁ¤º¸¼¾ÅÍ http://www.cancer.go.kr